Stockscreener 앱 받기
11.82
2.64%
-0.32
시간 외 거래:
11.85
0.03
+0.25%
전일 마감가:
$12.14
열려 있는:
$12.08
하루 거래량:
2.50M
Relative Volume:
0.78
시가총액:
$2.52B
수익:
$61.10M
순이익/손실:
$-138.36M
주가수익비율:
-8.7556
EPS:
-1.35
순현금흐름:
$-90.59M
1주 성능:
-5.89%
1개월 성능:
+5.07%
6개월 성능:
+24.95%
1년 성능:
+35.24%
1일 변동 폭
$11.60
$12.19
1주일 범위
$11.60
$12.66
52주 변동 폭
$5.80
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
명칭
Ocular Therapeutix Inc
전화
781-357-4000
주소
15 CROSBY DRIVE, BEDFORD, MA
OCUL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
11.82 | 2.59B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-15 | 개시 | Chardan Capital Markets | Buy |
| 2025-04-08 | 개시 | William Blair | Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-03-11 | 개시 | Needham | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-20 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-05-31 | 재개 | Piper Sandler | Overweight |
| 2024-02-09 | 개시 | BofA Securities | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-08-10 | 재개 | Berenberg | Buy |
| 2021-08-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-11-13 | 재확인 | Raymond James | Strong Buy |
| 2020-08-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-03 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2019-05-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-21 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-11-15 | 개시 | Raymond James | Strong Buy |
| 2018-09-07 | 개시 | Piper Jaffray | Overweight |
| 2017-10-24 | 개시 | Guggenheim | Buy |
| 2017-07-26 | 개시 | H.C. Wainwright | Buy |
| 2017-07-12 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-06-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-08-11 | 개시 | JMP Securities | Mkt Outperform |
| 2016-02-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | 개시 | Morgan Stanley | Overweight |
모두보기
Ocular Therapeutix Inc 주식(OCUL)의 최신 뉴스
Ocular Therapeutix (NASDAQ:OCUL) Surprises With Q3 CY2025 Sales - Yahoo Finance UK
BofA Bullish on Ocular Therapeutix (OCUL) as AXPAXLI Targets Superiority Label and Faster Regulatory Path in Wet AMD - Finviz
Voya Investment Management LLC Trims Position in Ocular Therapeutix, Inc. $OCUL - MarketBeat
Ocular Therapeutix Earnings Notes - Trefis
Assenagon Asset Management S.A. Sells 148,100 Shares of Ocular Therapeutix, Inc. $OCUL - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Share Price Crosses Above 50 Day Moving AverageWhat's Next? - MarketBeat
Trading Systems Reacting to (OCUL) Volatility - Stock Traders Daily
Revenue per share of Ocular Therapeutix Inc – BER:0OT - TradingView — Track All Markets
Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt? - 富途牛牛
Aug Action: Is Ocular Therapeutix Inc. (0OT) stock among top earnings playsMarket Sentiment Report & High Yield Stock Recommendations - Улправда
What is the fair value of Ocular Therapeutix Inc. stock nowTrade Volume Report & Long Hold Capital Preservation Plans - ulpravda.ru
Can Ocular Therapeutix Inc. stock hit analyst price targetsMarket Performance Recap & Capital Protection Trade Alerts - ulpravda.ru
Is Ocular Therapeutix Inc. (0OT) stock worth buying before Fed action2025 Top Gainers & Verified Short-Term Plans - ulpravda.ru
Is Ocular Therapeutix Inc. (0OT) stock among top earnings playsMarket Trend Summary & Reliable Breakout Forecasts - Улправда
Volume Summary: What is the fair value of Ocular Therapeutix Inc. stock now - ulpravda.ru
Can Ocular Therapeutix Inc. (0OT) stock retain market dominanceEarnings Recap Summary & Weekly Stock Performance Updates - DonanımHaber
How Ocular Therapeutix Inc. stock reacts to job market dataWeekly Trading Summary & Real-Time Buy Signal Alerts - DonanımHaber
What makes Ocular Therapeutix Inc. stock attractive to growth funds2025 Market WrapUp & Real-Time Market Sentiment Reports - DonanımHaber
Why analysts raise outlook for Ocular Therapeutix Inc. (0OT) stock2025 Pullback Review & Community Trade Idea Sharing Platform - Улправда
Is Ocular Therapeutix Inc. stock in correction or buying zoneQuarterly Profit Report & Smart Swing Trading Alerts - Улправда
How Ocular Therapeutix Inc. stock benefits from global expansion2025 Fundamental Recap & Community Verified Trade Alerts - Улправда
Will Ocular Therapeutix Inc. stock reach all time highs in 2025Trade Risk Assessment & Stepwise Swing Trade Plans - ulpravda.ru
Ocular Therapeutix (NASDAQ:OCUL) Stock Price Down 4.3%What's Next? - MarketBeat
Ocular Therapeutix enters quiet period ahead of SOL-1 milestone - MSN
Assessing Ocular Therapeutix (OCUL) Valuation After Accelerated FDA Filing Plan for AXPAXLI in Wet AMD - Sahm
Ocular Therapeutix stock could see 45% upside if trial succeeds, TD Cowen says - Investing.com Canada
RBC Capital Adjusts Ocular Therapeutix Price Target to $24 From $17, Maintains Outperform Rating - marketscreener.com
Ocular Therapeutix prepares NDA submission for wet AMD drug - MSN
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Avoiding Lag: Real-Time Signals in (OCUL) Movement - news.stocktradersdaily.com
Ocular Therapeutix Inc. (OCUL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
H.C. Wainwright Lifts Ocular Therapeutix, Inc. (OCUL) Price Target Following Intravitreal Implant FDA Submission - Insider Monkey
15 Best Biotech Stocks to Buy According to Wall Street Analysts - Insider Monkey
Chardan Capital Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Ocular Therapeutix (OCUL) Hits 4-Year High on Axpaxli NDA Application - Insider Monkey
EyePoint Pharmaceuticals (EYPT) Maintains Positive Outlook Amid Competitive Dynamics - GuruFocus
Is Ocular Therapeutix Inc a good long term investmentAnalyst Downgrades & Big Gains Low Investment - earlytimes.in
(OCUL) Stock Soars on Accelerated Wet AMD NDA – Price, Forecast & Risk Analysis as of December 9, 2025 - ts2.tech
Ocular Therapeutix's (OCUL) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
Chardan Capital Maintains Buy Rating on OCUL with $21 Price Targ - GuruFocus
Ocular Therapeutix plans for NDA submission of AXPAXLI for wet AMD - Eyes On Eyecare
Ocular Therapeutix: Not So Fast On The Single-Trial Bet (Rating Downgrade) (NASDAQ:OCUL) - Seeking Alpha
Ocular Therapeutix stock price target raised to $30 by RBC on wAMD trial outlook - Investing.com Canada
Ocular Therapeutix stock hits 52-week high at 14.79 USD By Investing.com - Investing.com Canada
HC Wainwright & Co. Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Citizens reiterates Market Outperform rating on Ocular Therapeutix stock By Investing.com - Investing.com Canada
OCUL Stock Surge: Analysts Weigh In - StocksToTrade
Ocular Therapeutix stock soars after plan to accelerate AXPAXLI submission By Investing.com - Investing.com Australia
Ocular Therapeutix stock soars after plan to accelerate AXPAXLI submission - Investing.com
Ocular Therapeutix Stock Skyrockets On Faster FDA Path For Vision Drug - Sahm
Ocular Therapeutix Inc (OCUL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.57%
자본화:
|
볼륨(24시간):